-
FibroGen Staring At Multi-Year Lows Following Adverse Roxadustat AdCom Verdict; How Hard Will The Stock Likely Fall?
Friday, July 16, 2021 - 6:20am | 726Read More...FibroGen, Inc.’s (NASDAQ: FGEN) shares are sinking to their lowest level since late June 2016. FibroGen’s AdCom Snub FibroGen said late Thursday that the Food and Drug Administration’s Cardiovascular and Renal Drugs Advisory Committee met to discuss the new drug...
-
Ahead Of AdComm AstraZeneca, FibroGen's Roxadustat Hit With Safety, Efficacy Questions
Tuesday, July 13, 2021 - 1:03pm | 376Read More...Ahead of Thursday's meeting of the FDA's Cardiovascular and Renal Drugs Advisory Committee, the agency is raising fresh doubts on the safety of AstraZeneca Plc's (NASDAQ: AZN) and FibroGen Inc's (NASDAQ: FGEN) anemia drug roxadustat. FDA staffers flagged...
-
Goldman Comments On Vertex Pharmaceuticals Following FDA Approval
Thursday, July 2, 2015 - 1:41pm | 242Read More...Shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) were trading higher by nearly 4 percent on Thursday after the FDA approved the company's Orkambi (lumacafor/ivacaftor) for the treatment of cystic fibrosis patients 12 years and older. Commenting on the FDA's approval, Terence Flynn, PhD...
-
Vertex Shares Rally As FDA Panel Backs Orkambi; HC Wainwright Analyst Offers Thoughts
Wednesday, May 13, 2015 - 10:26am | 419Read More...H.C. Wainwright commented on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Wednesday following the FDA AdCom endorsement to approve Orkambi as the stock surged over 5 percent in pre-market trading. Analyst Andrew S. Fein believed that since the Phase 3 win and going into the AdCom, “...
